Friedreich's ataxia real-world treatment uptake reveals the access-versus-efficacy gap

Reading the signal

The first approved disease-modifying therapy for Friedreich's ataxia entered the market in 2023. The pivotal trial established efficacy, the label specifies the eligible population, and the price point reflects the ultra-rare status. Real-world uptake to date has been slower and more uneven than the pivotal trial population shape would have predicted.

Real-world data from registries and from the patient-organisation surveys make several patterns visible:

• Patients in proximity to neurology specialist centres with Friedreich's ataxia experience are accessing the therapy at higher rates than patients in regions without such centres
• Payer prior-authorisation requirements are more variable than for conventional neurology approvals, with some payers requiring documentation of disease progression that older patient cohorts do not have
• Patient-specialist matching is uneven: some adult patients diagnosed in childhood are now followed in general neurology rather than specialist Friedreich's ataxia care, and the connection from general-neurology referral to specialist-prescriber decision is taking time to establish

The therapy is reaching the patients it should reach, but the uptake curve is more gradual and more geographically variable than the trial population would have suggested.

Commercial implications

For sponsors of approved ultra-rare neurological therapies and for sponsors with similar approvals in development:

1. Specialist-centre infrastructure is the rate-limit on uptake, not awareness. Where specialist centres exist, uptake is closer to expectations; where they do not, the gap is material. Investment in specialist-centre support (medical-affairs engagement, registry funding, fellowship support) is commercially leveraged.
2. Payer prior-authorisation criteria need to be co-designed at launch. Prior-authorisation criteria that ask for evidence patients do not have are not protecting payer budgets; they are delaying clinically appropriate access, and the resulting uptake-curve damage is hard to reverse.
3. The patient-finding pathway is part of the launch. Connecting the diagnosed-but-not-actively-followed patient population to specialist care at launch is a launch deliverable, not a post-launch optimisation.

What we are watching

• Real-world uptake curves at twelve, twenty-four and thirty-six months post-launch and the gradient by region
• Registry-based effectiveness data and how it compares to the pivotal trial efficacy data, particularly in patient cohorts that fall outside the strict trial inclusion criteria
• Adjacent ultra-rare neurology approvals (in spinocerebellar ataxia, in Pompe disease, in Niemann-Pick C) and whether they are designing the launch operating model to avoid the uptake-curve issues seen in Friedreich's ataxia